Strides Arcolab Ltd :

840.95 -3.65 [-0.43%]

ISIN: INE939A01011 | NSE: STAR | Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln | BSE Code: 532531 | Comments

Price Information
• Open	850.00
• High	851.00
• Low	838.00
• Previous Close	844.60
• Shares Traded	4451
• 52 Wk High Price	1224.90
• 52 Wk High Date	-
• 52 Wk Low Price	675.25
• 52 Wk Low Date	-
• Face Value	10.00

Fundamentals
• Market Capital (Rs.cr)	5101.33
• EPS (Rs.)(TTM)	21.36
• P/E Ratio(TTM)	40.44
• Book Value (Rs.)	232.30
• Price to Book Value	3.72
• Equity (Rs.cr.)	59.05
• Traded Value (Rs.lac)	317.56

Corporate Actions
Ex-Date	Purpose (Rs.)
2011-05-18	15% Dividend (1.5)
2012-05-14	20% Dividend (2)
2013-05-30	20% Dividend (2)

Index Names
• BSE-500

Related Companies
Stock Name	Price

CIPLA	379.85
JBCHEPHARM	77.85
JAYANTVITAMINS	3.00	-
MERIND	200.00	-
PIRHEALTH	551.80
RANBAXY	352.50
UNICHEMLAB	166.55
ALEMBICLTD	19.70
LYKALABS	10.46
TTKHEALTH	538.00

Share Tips for Strides Arcolab Ltd

NIFTY OUTLOOK FOR 19/06/2013 : RUPEE TR (08:32PM, Jun 18 '13)

NIFTY OUTLOOK FOR 18/06/2013 : RUPEE TR (08:00PM, Jun 17 '13)

NIFTY OUTLOOK FOR 17/06/2013 : RUPEE T (07:59PM, Jun 15 '13)

Market outlook : Had u remember our yes (08:14AM, Jun 14 '13)

NIFTY OUTLOOK FOR 14/06/2013 : AGAIN R (07:55PM, Jun 13 '13)

Mutual funds holding in Strides Arcolab Ltd

Baroda Pioneer Growth Fund - Growth

SBI Magnum Global Fund 94 - Growth

HDFC Capital Builder Fund - Growth

SBI Magnum Sector Umbrella - Emerging Businesses Fund - Growth

HDFC Long Term Advantage Fund - Growth

Key Financials	Latest Qrtr.	Trailing Yr.	Full Yr.
• Year End	Mar, 2013	Mar, 2013	Dec, 2012
• Sales (Rs.cr)	161.34	752.93	712.01
• Net Profit (Rs.cr)	30.74	126.16	99.88
• Net Profit Var (%)	589.00	65.00	41.00
• EPS (Rs)	-	21.36	16.60
• P/E Ratio	-	40.44	52.00
• Operating Profit Margin	-	14.87	-
• CPS (Rs.)	-	-	19.80
• P/C Ratio	-	-	43.60
• Div%	-	-	20.00

Announcements
11-04-2012	Strides Acrolab received final approval for the Vancomycin Hydrochloride capsules
23-12-2010	Strides Arcolab & Ascent Pharmahealth enters into scheme implementation agreement
05-12-2012	Strides Arcolab and Lilly enter strategic partnership to deliver high- quality, branded generic
11-12-2010	Strides Arcolab announces US FDA approval for Lidocaine Hydrochloride injection 16th sterile in
25-09-2012	Strides Arcolab received tentative approval for fixed dose combination of lamivudine, nevirapine a
26-04-2012	Strides acquires USFDA approved Sterile Formulations facility
13-10-2012	Strides Acrolab received final approval for
18-10-2012	Strides Acrolab received final approval for Fludarabine Phosphate injection
21-09-2011	Strides Acrolab received final approval for the Vancomycin Hydrochloride injection
01-07-2011	Strides announces European approval for its Oral Dosage Oncology facility
15-09-2011	Strides announces European approval for Oxaliplatin injection
18-11-2010	Strides Arcolab allots equity shares
03-04-2012	Strides Arcolab announces Health Canada approval for Tobramycin Injection
30-12-2010	Strides Arcolab announces sale of product portfolio by Akorn-Strides LLC to Pfizer Inc
28-07-2011	Strides Arcolab announces USFDA approval for Acarbose tablets
28-07-2012	Strides Arcolab appoints director
09-02-2011	Strides Arcolab grants options
20-10-2011	Strides Arcolab receives approval for Bupivacaine Hydrochloride injections
11-10-2011	Strides Arcolab receives approval for Cladribine Injection
02-11-2011	Strides Arcolab receives approval for Doxorubicin Injection
19-10-2012	Strides Arcolab receives two more approvals for Oncology Products
11-05-2012	Strides Arcolab receives US FDA approval for Acetazolamide Injection
29-11-2012	Strides Arcolab receives US FDA approval for Ifosfamide Injection
26-07-2011	Strides Arcolab receives USFDA approval for Gemcitabine for injection USP
19-04-2011	Strides Arcolab receives USFDA approval For its new sterile injectable facility
31-03-2012	Strides Arcolab receives USFDA approval for Methotrexate Injection
01-12-2010	Strides Arcolab receives USFDA approval for Midazolam Hydrochloride injection
25-02-2011	Strides Arcolab recommends dividend
24-01-2012	Strides Arcolab sells its generic pharmaceuticals operations in Australia & Southeast Asia to Watson
12-02-2011	Strides Arcolab to announce financial results
11-11-2011	Strides Arcolab to issue warrants

Gross Deliverables

Date Del. Shares Trd. Qty. Del.(%) Del. Value Turnover

17-06-2013 1569 5101 30.76 1337808 4366.16
13-06-2013 3728 8901 41.88 3269829 7845.58
07-06-2013 14233 48253 29.50 12506537 43023.50
28-05-2013 4859 12367 39.29 4306046 11007.40
24-05-2013 178179 204650 87.07 159024758 180662.00

Block Deals

Deal Date Client Name Type Qty Price

11-06-2012 SHIVANAND SHANKAR MANKEKAR B 91000 690.00
11-06-2012 OM KEDAR INVESTMENTS S 91000 690.00
11-06-2012 SHIVANAND SHANKAR MANKEKAR (HUF) B 150000 700.00
11-06-2012 OM KEDAR INVESTMENTS S 150000 700.00

Note:

- % change is w.r.t. Prev. Close
- On ex-date % change is w.r.t. open price
- On the date ofmovement of security from/to trade for trade segment, % change is w.r.t. open price
- 52 week high & 52 week low prices are based on the trade date & not adjusted with corporate action

Comment(s) posted on Strides Arcolab Ltd

Hot Searches • jindalswhl • hanung • orientb • jayant • eleco • spicejet • gati • atlanta • mrpl • escorts

Date	Del. Shares	Trd. Qty.	Del.(%)	Del. Value	Turnover
17-06-2013	1569	5101	30.76	1337808	4366.16
13-06-2013	3728	8901	41.88	3269829	7845.58
07-06-2013	14233	48253	29.50	12506537	43023.50
28-05-2013	4859	12367	39.29	4306046	11007.40
24-05-2013	178179	204650	87.07	159024758	180662.00

Deal Date	Client Name	Type	Qty	Price
11-06-2012	SHIVANAND SHANKAR MANKEKAR	B	91000	690.00
11-06-2012	OM KEDAR INVESTMENTS	S	91000	690.00
11-06-2012	SHIVANAND SHANKAR MANKEKAR (HUF)	B	150000	700.00
11-06-2012	OM KEDAR INVESTMENTS	S	150000	700.00